Stock Financial Ratios


ALBO / Albireo Pharma, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price33.00
Volume162,000.00
Market Cap ($M)43.78
Enterprise Value ($M)-17.90
Book Value ($M)26.44
Book Value / Share12.39
Price / Book1.69
NCAV ($M)26.78
NCAV / Share12.55
Price / NCAV5.10
Income Statement (mra) ($M)
Revenue0.00
EBITDA0.00
Net Income-13.76
Balance Sheet (mrq) ($M)
Cash & Equivalents57.07
Cash / Share26.75
Assets58.59
Liabilities7.97
Quick Ratio13.91
Current Ratio13.91
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.52
Return on Assets (ROA)-0.48
Return on Equity (ROE)-0.52
Identifiers and Descriptors
CUSIP09064M204
Central Index Key (CIK)1322505
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)8.90
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Current Portion Of Long Term Debt Per Share0.69
Accounts Payable Per Share0.74
Assets Current Per Share26.90
Inventory Per Share0.00
Liabilities Per Share3.74
Intangibles Per Share0.47
Cash Per Share26.75
Property Plant And Equipment Per Share0.09
Liabilities Current Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Cash And Equivalents Per Share26.75
Property Plant And Equipment Gross Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Non Current Per Share0.24
Debt Per Share0.69
Accounts Receivable Per Share0.01
Assets Other Current Per Share0.00
Equity Per Share32.39
Inventory Finished Goods Per Share0.00
Retained Earnings Per Share-21.23
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Additional Paid In Capital Per Share53.20
Assets Per Share27.46
Accumulated Depreciation And Depletion Per Share0.00
Property Plant And Equipment Net Per Share0.09
Goodwill Per Share8.09
Minority Interest Per Share0.00
Liabilities And Stock Equity Per Share36.13

Related News Stories

BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation

13h reuters
* ALBIREO PHARMA - JAPAN‘S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN (7-0)

10 Strong Buy Stocks That Are Better Than Bitcoin | InvestorPlace

2017-12-14 investorplace
No one can deny the huge hype bitcoin is generating right now … and for lucky investors, it has also proved a very profitable investment. But with such huge gains come huge risks — and even greater volatility. (274-4)

Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars

2017-12-07 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day earlier. (273-3)

Albireo Pharma: Updates To Thesis

2017-11-17 seekingalpha
Shares have risen nearly 20% since my initial write-up and I believe the initial bull thesis remains intact. (72-2)

Featured Company News - Albireo Pharma to Present Final Results of Phase-2 Study of A4250 in Children with Cholestatic Liver Disease at The Liver Meeting(R) 2017

2017-10-24 accesswire
LONDON, UK / ACCESSWIRE / October 24, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Albireo Pharma, Inc. (NASDAQ: ALBO), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=ALBO. The Company announced on October 20, 2017, that it will present the final results from its Phase-2 clinical trial of lead product candidate A4250 in children with cholestatic liver disease at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2017 in Washington, D. (22-0)

CUSIP: 09064M204